A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2016
At a glance
- Drugs LY 3200327 (Primary) ; LY 3200327 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 15 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.